Statements (57)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:Company
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Aintree_Grand_National
gptkb:The_Grand_National gptkb:2021_Grand_National gptkb:Grand_National |
gptkbp:acquisition |
Acquired several companies
|
gptkbp:awards |
Various industry awards
|
gptkbp:clinical_trial |
Collaboration with universities
Partnerships with pharmaceutical companies Involvement in clinical research Development of new diagnostic tests Participation in international studies |
gptkbp:community_engagement |
Educational programs
Health awareness campaigns Charity partnerships |
gptkbp:employees |
Over 1,000
|
gptkbp:founded |
gptkb:1982
|
gptkbp:founder |
Dr. Peter Fitz Gerald
|
gptkbp:global_presence |
Worldwide
|
gptkbp:headquarters |
Crumlin, Northern Ireland
|
https://www.w3.org/2000/01/rdf-schema#label |
Randox Health
|
gptkbp:industry |
Healthcare
|
gptkbp:innovation |
Health screening technology
|
gptkbp:is_tested_for |
Genetic testing
Allergy testing Toxicology testing Drug testing COVID-19 testing Infectious disease testing Nutritional testing Cardiac testing Hormone testing |
gptkbp:market |
Strong presence in Europe
Growing presence in Asia Expanding presence in North America Emerging presence in Africa Established presence in the Middle East |
gptkbp:parent_company |
Randox Laboratories Ltd.
|
gptkbp:partnerships |
Various healthcare organizations
|
gptkbp:products |
Diagnostic tests
|
gptkbp:regulatory_compliance |
ISO certified
CE marked products FDA approved tests |
gptkbp:research_focus |
Biomarker discovery
|
gptkbp:services |
Laboratory services
|
gptkbp:sustainability_initiatives |
Energy efficiency measures
Environmental responsibility programs Community support initiatives Sustainable sourcing practices Waste reduction efforts |
gptkbp:technology |
gptkb:Database_Management_System
Mobile health applications Telehealth solutions Automated laboratory systems Point-of-care testing devices |
gptkbp:website |
www.randoxhealth.com
|